Which has higher valuation and earnings, HYFT or TKNO?

Alpha Teknova has higher revenue and earnings than MindWalk. Alpha Teknova is trading at a lower price-to-earnings ratio than MindWalk, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MindWalk $17.59M 3.99 -$21.69M -$0.20 N/A Alpha Teknova $40.52M 7.22 -$17.26M -$0.32 N/A

Is HYFT or TKNO more profitable?

Alpha Teknova has a net margin of -41.07% compared to MindWalk's net margin of -66.79%. Alpha Teknova's return on equity of -24.32% beat MindWalk's return on equity. Company Net Margins Return on Equity Return on Assets MindWalk -66.79% -69.37% -39.74% Alpha Teknova -41.07% -24.32% -16.34%

Which has stronger earnings & valuation, NAGE or HYFT?

Niagen Bioscience has higher revenue and earnings than MindWalk. MindWalk is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Niagen Bioscience $130.42M 2.02 $17.38M $0.21 15.76 MindWalk $17.59M 3.99 -$21.69M -$0.20 N/A

Do analysts recommend HYFT or NLTX?

MindWalk currently has a consensus target price of $5.00, suggesting a potential upside of 228.95%. Given MindWalk's stronger consensus rating and higher possible upside, equities analysts clearly believe MindWalk is more favorable than Neoleukin Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MindWalk 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60 Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

MindWalk (HYFT) Competitors

$1.52 -0.03 (-1.94%)

Closing price 06/25/2026 04:00 PM Eastern

Extended Trading

$1.52 -0.01 (-0.33%)

As of 04:26 AM Eastern

Compare

HYFT vs. TKNO, NMRA, BCYC, NAGE, and NLTX

Should you buy MindWalk stock or one of its competitors? MarketBeat compares MindWalk with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MindWalk include Alpha Teknova (TKNO), Neumora Therapeutics (NMRA), Bicycle Therapeutics (BCYC), Niagen Bioscience (NAGE), and Neoleukin Therapeutics (NLTX). These companies are all part of the "pharmaceutical products" industry.

How does MindWalk compare to Alpha Teknova?

MindWalk (NASDAQ:HYFT) and Alpha Teknova (NASDAQ:TKNO) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment.

MindWalk presently has a consensus target price of $5.00, indicating a potential upside of 228.95%. Alpha Teknova has a consensus target price of $8.00, indicating a potential upside of 46.52%. Given MindWalk's stronger consensus rating and higher possible upside, equities analysts clearly believe MindWalk is more favorable than Alpha Teknova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MindWalk	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Alpha Teknova	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Alpha Teknova has a net margin of -41.07% compared to MindWalk's net margin of -66.79%. Alpha Teknova's return on equity of -24.32% beat MindWalk's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MindWalk	-66.79%	-69.37%	-39.74%
Alpha Teknova	-41.07%	-24.32%	-16.34%

In the previous week, Alpha Teknova had 1 more articles in the media than MindWalk. MarketBeat recorded 2 mentions for Alpha Teknova and 1 mentions for MindWalk. MindWalk's average media sentiment score of 1.87 beat Alpha Teknova's score of 0.94 indicating that MindWalk is being referred to more favorably in the media.

Company	Overall Sentiment
MindWalk	Very Positive
Alpha Teknova	Positive

Alpha Teknova has higher revenue and earnings than MindWalk. Alpha Teknova is trading at a lower price-to-earnings ratio than MindWalk, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MindWalk	$17.59M	3.99	-$21.69M	-$0.20	N/A
Alpha Teknova	$40.52M	7.22	-$17.26M	-$0.32	N/A

6.7% of MindWalk shares are held by institutional investors. Comparatively, 13.8% of Alpha Teknova shares are held by institutional investors. 6.8% of MindWalk shares are held by insiders. Comparatively, 12.5% of Alpha Teknova shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

MindWalk has a beta of 0.79, indicating that its share price is 21% less volatile than the broader market. Comparatively, Alpha Teknova has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market.

Summary

Alpha Teknova beats MindWalk on 9 of the 16 factors compared between the two stocks.

How does MindWalk compare to Neumora Therapeutics?

Neumora Therapeutics (NASDAQ:NMRA) and MindWalk (NASDAQ:HYFT) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings and profitability.

Neumora Therapeutics currently has a consensus price target of $6.86, indicating a potential upside of 354.12%. MindWalk has a consensus price target of $5.00, indicating a potential upside of 228.95%. Given Neumora Therapeutics' higher possible upside, equities research analysts plainly believe Neumora Therapeutics is more favorable than MindWalk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neumora Therapeutics	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60
MindWalk	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

47.7% of Neumora Therapeutics shares are held by institutional investors. Comparatively, 6.7% of MindWalk shares are held by institutional investors. 26.9% of Neumora Therapeutics shares are held by company insiders. Comparatively, 6.8% of MindWalk shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Neumora Therapeutics has a beta of 2.73, indicating that its stock price is 173% more volatile than the broader market. Comparatively, MindWalk has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market.

Neumora Therapeutics has a net margin of 0.00% compared to MindWalk's net margin of -66.79%. MindWalk's return on equity of -69.37% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neumora Therapeutics	N/A	-181.70%	-119.15%
MindWalk	-66.79%	-69.37%	-39.74%

In the previous week, Neumora Therapeutics and Neumora Therapeutics both had 1 articles in the media. Neumora Therapeutics' average media sentiment score of 1.89 beat MindWalk's score of 1.87 indicating that Neumora Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Neumora Therapeutics	Very Positive
MindWalk	Very Positive

MindWalk has higher revenue and earnings than Neumora Therapeutics. MindWalk is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.33	N/A
MindWalk	$17.59M	3.99	-$21.69M	-$0.20	N/A

Summary

Neumora Therapeutics beats MindWalk on 8 of the 13 factors compared between the two stocks.

How does MindWalk compare to Bicycle Therapeutics?

Bicycle Therapeutics (NASDAQ:BCYC) and MindWalk (NASDAQ:HYFT) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, dividends, analyst recommendations, earnings and profitability.

In the previous week, Bicycle Therapeutics and Bicycle Therapeutics both had 1 articles in the media. MindWalk's average media sentiment score of 1.87 beat Bicycle Therapeutics' score of 0.93 indicating that MindWalk is being referred to more favorably in the news media.

Company	Overall Sentiment
Bicycle Therapeutics	Positive
MindWalk	Very Positive

MindWalk has a net margin of -66.79% compared to Bicycle Therapeutics' net margin of -344.95%. Bicycle Therapeutics' return on equity of -35.74% beat MindWalk's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicycle Therapeutics	-344.95%	-35.74%	-29.54%
MindWalk	-66.79%	-69.37%	-39.74%

Bicycle Therapeutics has a beta of 1.54, meaning that its stock price is 54% more volatile than the broader market. Comparatively, MindWalk has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market.

86.2% of Bicycle Therapeutics shares are owned by institutional investors. Comparatively, 6.7% of MindWalk shares are owned by institutional investors. 22.9% of Bicycle Therapeutics shares are owned by insiders. Comparatively, 6.8% of MindWalk shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

MindWalk has lower revenue, but higher earnings than Bicycle Therapeutics. MindWalk is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicycle Therapeutics	$72.86M	3.84	-$218.96M	-$3.15	N/A
MindWalk	$17.59M	3.99	-$21.69M	-$0.20	N/A

Bicycle Therapeutics currently has a consensus target price of $14.00, indicating a potential upside of 249.13%. MindWalk has a consensus target price of $5.00, indicating a potential upside of 228.95%. Given Bicycle Therapeutics' higher probable upside, analysts clearly believe Bicycle Therapeutics is more favorable than MindWalk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
MindWalk	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Summary

Bicycle Therapeutics beats MindWalk on 9 of the 16 factors compared between the two stocks.

How does MindWalk compare to Niagen Bioscience?

Niagen Bioscience (NASDAQ:NAGE) and MindWalk (NASDAQ:HYFT) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation.

Niagen Bioscience currently has a consensus price target of $10.50, indicating a potential upside of 217.22%. MindWalk has a consensus price target of $5.00, indicating a potential upside of 228.95%. Given MindWalk's higher probable upside, analysts clearly believe MindWalk is more favorable than Niagen Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Niagen Bioscience	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
MindWalk	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Niagen Bioscience has higher revenue and earnings than MindWalk. MindWalk is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Niagen Bioscience	$130.42M	2.02	$17.38M	$0.21	15.76
MindWalk	$17.59M	3.99	-$21.69M	-$0.20	N/A

15.4% of Niagen Bioscience shares are held by institutional investors. Comparatively, 6.7% of MindWalk shares are held by institutional investors. 10.0% of Niagen Bioscience shares are held by company insiders. Comparatively, 6.8% of MindWalk shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Niagen Bioscience had 1 more articles in the media than MindWalk. MarketBeat recorded 2 mentions for Niagen Bioscience and 1 mentions for MindWalk. MindWalk's average media sentiment score of 1.87 beat Niagen Bioscience's score of 0.93 indicating that MindWalk is being referred to more favorably in the news media.

Company	Overall Sentiment
Niagen Bioscience	Positive
MindWalk	Very Positive

Niagen Bioscience has a net margin of 14.29% compared to MindWalk's net margin of -66.79%. Niagen Bioscience's return on equity of 22.68% beat MindWalk's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Niagen Bioscience	14.29%	22.68%	16.23%
MindWalk	-66.79%	-69.37%	-39.74%

Niagen Bioscience has a beta of 2.08, suggesting that its stock price is 108% more volatile than the broader market. Comparatively, MindWalk has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market.

Summary

Niagen Bioscience beats MindWalk on 12 of the 16 factors compared between the two stocks.

How does MindWalk compare to Neoleukin Therapeutics?

MindWalk (NASDAQ:HYFT) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap pharmaceutical preparations industry companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends and valuation.

6.7% of MindWalk shares are owned by institutional investors. Comparatively, 52.4% of Neoleukin Therapeutics shares are owned by institutional investors. 6.8% of MindWalk shares are owned by company insiders. Comparatively, 1.6% of Neoleukin Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

MindWalk has a beta of 0.79, indicating that its share price is 21% less volatile than the broader market. Comparatively, Neoleukin Therapeutics has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market.

In the previous week, MindWalk had 1 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 1 mentions for MindWalk and 0 mentions for Neoleukin Therapeutics. MindWalk's average media sentiment score of 1.87 beat Neoleukin Therapeutics' score of 0.00 indicating that MindWalk is being referred to more favorably in the media.

Company	Overall Sentiment
MindWalk	Very Positive
Neoleukin Therapeutics	Neutral

Neoleukin Therapeutics has a net margin of 0.00% compared to MindWalk's net margin of -66.79%. Neoleukin Therapeutics' return on equity of -37.22% beat MindWalk's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MindWalk	-66.79%	-69.37%	-39.74%
Neoleukin Therapeutics	N/A	-37.22%	-30.91%

MindWalk has higher revenue and earnings than Neoleukin Therapeutics. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than MindWalk, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MindWalk	$17.59M	3.99	-$21.69M	-$0.20	N/A
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A

MindWalk currently has a consensus target price of $5.00, suggesting a potential upside of 228.95%. Given MindWalk's stronger consensus rating and higher possible upside, equities analysts clearly believe MindWalk is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MindWalk	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

MindWalk beats Neoleukin Therapeutics on 11 of the 16 factors compared between the two stocks.

Get MindWalk News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HYFT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HYFT vs. The Competition

Export

Metric	MindWalk	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$71.54M	$777.78M	$4.33B	$12.27B
Dividend Yield	N/A	4.84%	11.45%	5.89%
P/E Ratio	-7.60	1.43	21.93	23.97
Price / Sales	3.99	118.23	154.26	99.70
Price / Cash	N/A	20.06	38.01	53.91
Price / Book	4.11	7.95	14.74	6.32
Net Income	-$21.69M	-$4.05M	$115.37M	$337.22M
7 Day Performance	-0.65%	-0.26%	-1.64%	-1.24%
1 Month Performance	-6.75%	0.56%	-2.83%	-0.63%
1 Year Performance	N/A	45.81%	11.30%	27.95%

MindWalk Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HYFT MindWalk	3.0183 of 5 stars	$1.52 -1.9%	$5.00 +228.9%	N/A	$71.54M	$17.59M	N/A	80	Gap Up
TKNO Alpha Teknova	1.94 of 5 stars	$5.24 flat	$8.00 +52.7%	+5.2%	$280.92M	$40.52M	N/A	240	Gap Down High Trading Volume
NMRA Neumora Therapeutics	4.4019 of 5 stars	$1.51 flat	$6.86 +354.1%	+86.9%	$279.77M	N/A	N/A	108	Gap Down
BCYC Bicycle Therapeutics	3.5912 of 5 stars	$4.00 -0.1%	$14.00 +250.4%	-43.5%	$278.89M	$72.86M	N/A	240
NAGE Niagen Bioscience	3.6561 of 5 stars	$3.50 flat	$10.50 +200.0%	-75.3%	$278.74M	$129.42M	16.67	120

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HYFT) was last updated on 6/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MindWalk (HYFT) Competitors

HYFT vs. TKNO, NMRA, BCYC, NAGE, and NLTX

How does MindWalk compare to Alpha Teknova?

Summary

How does MindWalk compare to Neumora Therapeutics?

Summary

How does MindWalk compare to Bicycle Therapeutics?

Summary

How does MindWalk compare to Niagen Bioscience?

Summary

How does MindWalk compare to Neoleukin Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HYFT vs. The Competition

MindWalk Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MindWalk (HYFT) Competitors

HYFT vs. TKNO, NMRA, BCYC, NAGE, and NLTX

How does MindWalk compare to Alpha Teknova?

Do analysts prefer HYFT or TKNO?

Is HYFT or TKNO more profitable?

Does the media favor HYFT or TKNO?

Which has higher valuation and earnings, HYFT or TKNO?

Do institutionals and insiders believe in HYFT or TKNO?

Which has more risk and volatility, HYFT or TKNO?

Summary

How does MindWalk compare to Neumora Therapeutics?

Do analysts prefer NMRA or HYFT?

Do insiders and institutionals have more ownership in NMRA or HYFT?

Which has more volatility and risk, NMRA or HYFT?

Is NMRA or HYFT more profitable?

Does the media refer more to NMRA or HYFT?

Which has preferable earnings & valuation, NMRA or HYFT?

Summary

How does MindWalk compare to Bicycle Therapeutics?

Does the media refer more to BCYC or HYFT?

Is BCYC or HYFT more profitable?

Which has more risk and volatility, BCYC or HYFT?

Do insiders & institutionals have more ownership in BCYC or HYFT?

Which has better earnings & valuation, BCYC or HYFT?

Do analysts recommend BCYC or HYFT?

Summary

How does MindWalk compare to Niagen Bioscience?

Do analysts recommend NAGE or HYFT?

Which has stronger earnings & valuation, NAGE or HYFT?

Do insiders and institutionals believe in NAGE or HYFT?

Does the media favor NAGE or HYFT?

Is NAGE or HYFT more profitable?

Which has more risk & volatility, NAGE or HYFT?

Summary

How does MindWalk compare to Neoleukin Therapeutics?

Do institutionals & insiders have more ownership in HYFT or NLTX?

Which has more volatility & risk, HYFT or NLTX?

Does the media prefer HYFT or NLTX?

Is HYFT or NLTX more profitable?

Which has preferable earnings and valuation, HYFT or NLTX?

Do analysts recommend HYFT or NLTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HYFT vs. The Competition

MindWalk Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools